• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿托伐他汀治疗对血脂异常患者红细胞膜流变特性、血脂谱和氧化状态的影响。

The effects of atorvastatin therapy on rheological characteristics of erythrocyte membrane, serum lipid profile and oxidative status in patients with dyslipidemia.

机构信息

Department of Medical Biochemistry, Recep Tayyip Erdoğan University, Rize, Turkey.

出版信息

J Membr Biol. 2012 Nov;245(11):697-705. doi: 10.1007/s00232-012-9441-7. Epub 2012 Jun 16.

DOI:10.1007/s00232-012-9441-7
PMID:22706680
Abstract

The statins, most commonly used in the treatment of hyperlipidemia, have certain beneficial effects including improved endothelial function, plaque stability and decreased oxidative stress and inflammation, beyond their lipid-lowering effect in plasma. We evaluated the pleiotropic impact of atorvastatin on erythrocyte structural/mechanical properties and lipid peroxidation in dyslipidemics. The study group included 44 patients with dyslipidemia and was divided into subgroups according to triglyceride and cholesterol levels as hypercholesterolemic (n = 29) and mixed-type hyperlipidemic (n = 15). Subjects were given 10 mg atorvastatin per day for 12 weeks. Changes in serum lipid composition, lipid contents, Na(+)/K(+)-ATPase activity and osmotic fragility in erythrocytes and oxidative stress parameters of erythrocytes and plasma were studied. Atorvastatin therapy improved the serum lipid profile of both subgroups. This alteration was accompanied by a decreased level of cholesterol in erythrocyte membranes. Moreover, enhanced activity of Na(+)/K(+)-ATPase in erythrocytes reflected the improvements in membrane lipids of both subgroups. However, a significant change was observed in osmotic fragility values of the mixed-typed dyslipidemic group. This treatment lowered the lipid peroxidation in plasma and erythrocytes and increased plasma total antioxidant capacity in all groups. The present study shows that the use of atorvastatin reversed the structural and functional features of erythrocyte membranes in dyslipidemic subjects. Also, hypolipidemic therapy had a beneficial impact on a balance between oxidant and antioxidant systems.

摘要

他汀类药物,最常用于治疗高脂血症,除了在血浆中降低血脂外,还有一定的有益作用,包括改善内皮功能、斑块稳定性和减少氧化应激和炎症。我们评估了阿托伐他汀对血脂异常患者红细胞结构/力学特性和脂质过氧化的多效性影响。研究组包括 44 名血脂异常患者,并根据甘油三酯和胆固醇水平分为高胆固醇血症亚组(n=29)和混合性高脂血症亚组(n=15)。患者每天服用 10 毫克阿托伐他汀,持续 12 周。研究了血清脂质组成、脂质含量、红细胞 Na(+)/K(+)-ATP 酶活性和渗透脆性以及红细胞和血浆的氧化应激参数的变化。阿托伐他汀治疗改善了两个亚组的血清血脂谱。这种改变伴随着红细胞膜胆固醇水平的降低。此外,红细胞 Na(+)/K(+)-ATP 酶活性的增强反映了两个亚组的膜脂质的改善。然而,混合性血脂异常组的渗透脆性值有显著变化。这种治疗降低了血浆和红细胞中的脂质过氧化作用,并增加了所有组的血浆总抗氧化能力。本研究表明,阿托伐他汀的使用逆转了血脂异常患者红细胞膜的结构和功能特征。此外,降脂治疗对氧化应激和抗氧化系统之间的平衡有有益的影响。

相似文献

1
The effects of atorvastatin therapy on rheological characteristics of erythrocyte membrane, serum lipid profile and oxidative status in patients with dyslipidemia.阿托伐他汀治疗对血脂异常患者红细胞膜流变特性、血脂谱和氧化状态的影响。
J Membr Biol. 2012 Nov;245(11):697-705. doi: 10.1007/s00232-012-9441-7. Epub 2012 Jun 16.
2
The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia.阿托伐他汀对2型高胆固醇血症患者红细胞膜及血脂的影响。
Eur J Clin Pharmacol. 2002 Nov;58(8):501-6. doi: 10.1007/s00228-002-0507-9. Epub 2002 Sep 28.
3
Physicochemical modifications induced by statins therapy on human erythrocytes membranes.他汀类药物治疗对人红细胞膜引起的物理化学修饰。
Wiad Lek. 2007;60(7-8):321-8.
4
[Erythrocyte fluidity in patients with hyperlipidemia during statins therapy].[他汀类药物治疗期间高脂血症患者的红细胞流动性]
Pol Arch Med Wewn. 2005 Jun;113(6):531-7.
5
Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties.阿托伐他汀治疗降低血浆胆固醇对红细胞力学性能的影响。
Clin Hemorheol Microcirc. 2007;36(1):25-33.
6
The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia.降脂治疗对血脂异常患者对氧磷酶活性的影响及其与氧化-抗氧化系统的关系。
Coron Artery Dis. 2004 Aug;15(5):277-83. doi: 10.1097/01.mca.0000135221.32523.a1.
7
The Effect of Combined Ezetimibe/Atorvastatin Therapy vs. Atorvastatin Monotherapy on the Erythrocyte Membrane Structure in Patients with Coronary Artery Disease: A Pilot Study.依折麦布/阿托伐他汀联合治疗与阿托伐他汀单药治疗对冠心病患者红细胞膜结构的影响:一项初步研究。
Adv Clin Exp Med. 2016 May-Jun;25(3):433-9. doi: 10.17219/acem/34791.
8
[The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia].[他汀类药物对血脂异常患者脂质过氧化及抗氧化酶活性的影响]
Przegl Lek. 2006;63(9):738-42.
9
Effects of atorvastatin and ezetimibe on endothelial function in dyslipidemic patients with chronic kidney disease.阿托伐他汀和依折麦布对慢性肾脏病血脂异常患者内皮功能的影响。
Clin Exp Nephrol. 2014 Oct;18(5):704-10. doi: 10.1007/s10157-013-0904-7. Epub 2013 Nov 7.
10
Effects of simvastatin and pravastatin on peroxidation of erythrocyte plasma membrane lipids in patients with type 2 hypercholesterolemia.辛伐他汀和普伐他汀对2型高胆固醇血症患者红细胞质膜脂质过氧化的影响。
Can J Physiol Pharmacol. 2003 May;81(5):485-92. doi: 10.1139/y03-042.

引用本文的文献

1
The Effect of Statin Therapy on Hemorheological Parameters of Patients with Clinically Silent Ischemic Foci of the Brain.他汀类药物治疗对脑临床无症状缺血灶患者血液流变学参数的影响。
Int J Mol Sci. 2025 Jul 22;26(15):7039. doi: 10.3390/ijms26157039.
2
Triglyceride-lowering effect of the aldose reductase inhibitor cemtirestat-another factor that may contribute to attenuation of symptoms of peripheral neuropathy in STZ-diabetic rats.醛糖还原酶抑制剂依帕司他降低甘油三酯的作用——可能有助于减轻链脲佐菌素糖尿病大鼠周围神经病变症状的另一个因素。
Naunyn Schmiedebergs Arch Pharmacol. 2020 Apr;393(4):651-661. doi: 10.1007/s00210-019-01769-1. Epub 2019 Dec 5.
3

本文引用的文献

1
Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.肥胖、代谢综合征和2型糖尿病中的血脂异常:他汀类药物治疗后降低残余风险的情况。
Open Cardiovasc Med J. 2011;5:24-34. doi: 10.2174/1874192401105010024. Epub 2011 Feb 24.
2
Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.最大剂量阿托伐他汀和瑞舒伐他汀治疗对葡萄糖稳态和炎症标志物的影响。
Am J Cardiol. 2011 Feb 1;107(3):387-92. doi: 10.1016/j.amjcard.2010.09.031.
3
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol.
瑞舒伐他汀对胆固醇正常的健康志愿者免疫系统的影响。
JCI Insight. 2019 Nov 1;4(21):131530. doi: 10.1172/jci.insight.131530.
4
Antioxidant Effects of Decoction on Dysfunctional Erythrocytes in High-Fat Diet-Induced Hyperlipidemic ApoE Mice.降脂饮对高脂饮食诱导的载脂蛋白 E 基因敲除小鼠功能异常红细胞的抗氧化作用。
Oxid Med Cell Longev. 2019 Mar 18;2019:5172480. doi: 10.1155/2019/5172480. eCollection 2019.
5
Effect of 405 nm low intensity irradiation on the absorption spectrum of in-vitro hyperlipidemia blood.405纳米低强度照射对体外高脂血症血液吸收光谱的影响。
Technol Health Care. 2018;26(S1):135-143. doi: 10.3233/THC-174302.
6
Chitosan treatment abrogates hypercholesterolemia-induced erythrocyte's arginase activation.壳聚糖治疗可消除高胆固醇血症诱导的红细胞精氨酸酶激活。
Saudi Pharm J. 2017 Jan;25(1):120-127. doi: 10.1016/j.jsps.2016.05.007. Epub 2016 May 26.
7
Longxuetongluo Capsule Improves Erythrocyte Function against Lipid Peroxidation and Abnormal Hemorheological Parameters in High Fat Diet-Induced ApoE-/- Mice.龙血通络胶囊改善高脂饮食诱导的ApoE-/-小鼠红细胞抗脂质过氧化功能及异常血液流变学参数。
Oxid Med Cell Longev. 2016;2016:2603219. doi: 10.1155/2016/2603219. Epub 2015 Nov 16.
8
Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics.控制不佳的2型糖尿病伴有红细胞以及凝血酶生成的纤维蛋白显著的形态学和超微结构变化:对诊断的意义。
Cardiovasc Diabetol. 2015 Mar 8;14:30. doi: 10.1186/s12933-015-0192-5.
9
Lipid-lowering efficacy of atorvastatin.阿托伐他汀的降脂疗效。
Cochrane Database Syst Rev. 2015 Mar 12;2015(3):CD008226. doi: 10.1002/14651858.CD008226.pub3.
10
Cholesterol forms and traditional lipid profile for projection of atherogenic dyslipidemia: lipoprotein subfractions and erythrocyte membrane cholesterol.胆固醇形成和传统血脂谱预测动脉粥样硬化性血脂异常:脂蛋白亚组分和红细胞膜胆固醇。
J Membr Biol. 2014 Feb;247(2):127-34. doi: 10.1007/s00232-013-9611-2. Epub 2013 Nov 16.
他汀类药物治疗稳定型冠心病患者的血脂和非脂生物标志物预测心血管事件。
J Am Coll Cardiol. 2011 Jan 4;57(1):63-9. doi: 10.1016/j.jacc.2010.06.052.
4
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.非诺贝特酸联合阿托伐他汀和依折麦布治疗混合性血脂异常患者的疗效和安全性。
Am Heart J. 2010 Oct;160(4):759-66. doi: 10.1016/j.ahj.2010.06.045.
5
Electronegative low-density lipoprotein is associated with dense low-density lipoprotein in subjects with different levels of cardiovascular risk.在具有不同心血管风险水平的受试者中,带负电的低密度脂蛋白与致密低密度脂蛋白相关。
Lipids. 2010 Jul;45(7):619-25. doi: 10.1007/s11745-010-3439-7. Epub 2010 Jun 24.
6
Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients.阿托伐他汀在高胆固醇血症患者中引起胰岛素抵抗并增加环境血糖。
J Am Coll Cardiol. 2010 Mar 23;55(12):1209-1216. doi: 10.1016/j.jacc.2009.10.053.
7
Influence of the use of statin on the stability of erythrocyte membranes in multiple sclerosis.他汀类药物的使用对多发性硬化症患者红细胞膜稳定性的影响。
J Membr Biol. 2010 Feb;233(1-3):127-34. doi: 10.1007/s00232-010-9232-y. Epub 2010 Feb 10.
8
Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database.他汀类药物对 HDL-C 的影响:与 LDL-C 变化无关的复杂过程:VOYAGER 数据库分析。
J Lipid Res. 2010 Jun;51(6):1546-53. doi: 10.1194/jlr.P002816. Epub 2009 Dec 2.
9
Does statin use improve pneumonia outcomes?他汀类药物的使用是否能改善肺炎的预后?
Chest. 2009 Nov;136(5):1381-1388. doi: 10.1378/chest.09-0941.
10
Adverse effects of statins - mechanisms and consequences.他汀类药物的不良反应——机制与后果
Curr Drug Saf. 2009 Sep;4(3):209-28. doi: 10.2174/157488609789006949. Epub 2009 Sep 1.